Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. large shareholder Venrock Healthcare Capital and related entities, together with individuals Nimish Shah and Bong Koh, report beneficial ownership of up to 5,676,370 shares of common stock as of June 30, 2026. This position, including common shares and Pre-Funded Warrants subject to limits, represents 9.99% of the outstanding common stock.
The ownership is held through Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, L.P., and Venrock Healthcare Capital Partners EG, L.P., along with their managing entities. Across these vehicles, the group holds common shares and Pre-Funded Warrants exercisable for additional common stock, all subject to a Beneficial Ownership Blocker that caps post-exercise ownership at 9.99% of Vor Biopharma’s outstanding shares, based on 54,185,877 shares outstanding as of May 7, 2026. All Reporting Persons report shared voting and dispositive power over the same 5,676,370 shares.
Vor Biopharma Inc. is the subject of an amended Schedule 13G filing by several Frazier Life Sciences-affiliated funds and entities, which together act as institutional investors rather than as individuals. The main holder, Frazier Life Sciences Public Fund, L.P., reports beneficial ownership of 2,258,001 shares of Vor Biopharma common stock, representing 4.2% of the class, with no sole voting or dispositive power and only shared powers through its control structure.
Additional Frazier vehicles report smaller positions: Frazier Life Sciences XI, L.P. holds 21,114 shares (0.0% of the class) and Frazier Life Sciences XII, L.P. holds 264,824 shares (0.5% of the class), each with shared voting and dispositive power only. All percentage interests are calculated based on 54,185,877 shares outstanding as of May 7, 2026. The filers state that no individual committee members are attributed beneficial ownership and that the filing does not admit membership in any group.
Vor Biopharma Inc. common stock is reported as being beneficially owned by Verve Capital LimitedJune 30, 2026, Verve Capital reports beneficial ownership of 3,410,892 shares of Vor Biopharma common stock, representing 6.3% of the class. Verve Capital has sole voting power and sole dispositive power over all of these shares, with no shared voting or dispositive power.
The ownership percentage is based on 54,185,877 shares outstanding as of May 7, 2026, as disclosed by Vor Biopharma, plus 269,874 shares issued to Verve Capital upon exercise of Pre-Funded Warrants on May 29, 2026. Verve Capital is organized under the laws of Samoa and signed this amendment through director Hongtu Zhu on August 13, 2026.
Vor Biopharma Inc. reported a net loss of $62.8 million for the quarter ended June 30 2026, a sharp improvement from a $1.57 billion loss a year earlier that was driven by a large non‑cash warrant revaluation and an upfront license charge. For the first six months of 2026, net loss was $282.4 million.
Operating expenses declined to $47.9 million in the quarter, with research and development at $25.9 million versus $261.5 million a year ago, mainly reflecting the absence of the prior‑year $222.6 million telitacicept license expense and lease‑termination costs. General and administrative expenses rose to $21.9 million, driven by higher stock‑based compensation, commercial build‑out, and professional fees.
Cash, cash equivalents and marketable securities totaled $466.1 million at June 30 2026. Including $48.9 million of gross proceeds from July at‑the‑market stock sales, management expects funding to support operations into early 2029 while advancing global Phase 3 trials of telitacicept in generalized myasthenia gravis and Sjögren’s disease.
VOR Biopharma Inc’s common stock is reported as beneficially owned by investment manager FMR LLC and by Abigail P. Johnson on a Schedule 13G/A. FMR LLC and Johnson each report beneficial ownership of 6,509,996 shares of VOR Biopharma common stock, representing 12.0% of the class. FMR LLC reports 6,509,263 shares with sole voting power and the full 6,509,996 shares with sole dispositive power, with no shared voting or dispositive power. One or more other persons have rights to dividends or sale proceeds from these shares, but no such person holds more than five percent of VOR Biopharma’s outstanding common stock.
FMR LLC reports beneficial ownership of 4,932,149 shares of Vor Biopharma Inc. common stock, representing 9.1% of the class as of June 30, 2026. These shares are reported with sole dispositive power and essentially all sole voting power.
Abigail P. Johnson is reported with sole dispositive power over the same 4,932,149 shares, but no sole or shared voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of Vor Biopharma’s outstanding common stock.
BlackRock, Inc. reported beneficial ownership of common stock of VOR BIOPHARMA INC on a Schedule 13G. BlackRock and certain of its business units collectively beneficially own 3,099,259 shares of VOR Biopharma common stock, representing 5.7% of the outstanding class.
BlackRock has sole voting power over 3,057,613 shares and sole dispositive power over 3,099,259 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends or sale proceeds, but no single client holds more than five percent of the company’s outstanding common shares.
RA Capital Management and affiliated entities report beneficial ownership of 12,937,855 shares of Vor Biopharma common stock, representing 19.9% of the class. The position includes common shares, common stock warrants, pre-funded warrants and stock options held for the benefit of RA Capital.
On July 16, 2026, the RA Capital Healthcare Fund exercised pre-funded warrants to purchase 2,100,000 shares at $0.002 per share on a cashless basis, resulting in 2,099,787 shares issued and 213 shares withheld to satisfy the exercise price. The pre-funded warrants contain a Beneficial Ownership Blocker that prevents exercises taking ownership above 19.99% of outstanding shares; the fund is currently limited to 12,937,855 shares.
The reported ownership percentage is calculated using 54,185,582 shares outstanding as of May 5, 2026, plus the 2,099,787 newly issued shares. Andrew Levin resigned from Vor Biopharma’s Board of Directors effective July 6, 2026.
RA Capital Healthcare Fund LP, an affiliate of RA Capital Management and a 10% owner of Vor Biopharma, exercised pre-funded warrants for 2,100,000 common shares at $0.002 per share. The exercise was cashless, so 213 shares valued at $19.75 were withheld to pay the exercise price and 2,099,787 shares were issued to the Fund. Following the transaction, the Fund continued to hold 7,900,000 pre-funded warrants, which are immediately exercisable with no expiration but subject to a 19.99% beneficial ownership cap. RA Capital Management, its general partner, and Dr. Peter Kolchinsky and Mr. Rajeev Shah disclaim beneficial ownership beyond their pecuniary interest, and the securities are held directly by the Fund.
Vor Biopharma Inc. director David Zaccardelli has filed an initial ownership report on Form 3. The filing lists no reportable stock or derivative positions and shows no buy, sell, or other share transactions, indicating this is a baseline regulatory disclosure rather than an active trade.